Please wait...

You selected inventions in category Biotech

  • Oxygen Carrying Perfusate for Organ TransplantationOxygen Carrying Perfusate for Organ...
      Preview
      Description

      This artificial red cell does not have pathogen and blood type antigen, and can be stored at room temperatures for years. Safety and efficacy as a resuscitative fluid for hemorrhagic shock and prime fluid for extracorporeal membrane oxygenation (ECMO) are confirmed in preclinical studies. It is expected that the artificial red cell can be utilized temporally for improving storage condition of organ transplant. The artificial red cell is expected to supply oxygen at an appropriate temperature, like does erythrocyte, from the beginning of resection of an organ from a donor and during the transportation to a recipient in a remote hospital, and it can avoid ischemia reperfusion injury and cold-induced injury.

      Features and Advantages:
      * Encapsulates a concentrated Hb solution within a phospholipid vesicle
      * Utilizable without worrying about infection and blood type mismatching
      * Indicates high biocompatibility
      * Storable for over years at room temperature
      * Mass production available

      Possible Applications:
      * Perfusate for Organ Transplantation
      * Prime fluid for ECMO
      * Fluid resuscitation, fluid replacement

      Full details Contact close
    • Novel Antiprotozoal AgentNovel Antiprotozoal Agent
        Preview
        Description

        The technology relates to a novel compound having antiprotozoal activity, which is particularly preferred as an antileishmania agent. The agent has a similar activity level as the amphotericin B which is one of antileishmania drugs currently used. Furthermore, the agent shows low cytotoxic effect. Since the backbone of the agent wholly differs from that of the amphotericin B, it is suggested that the mode of action is also different. This indicates that this agent can be second-line drug when the drug-resistant strains appear.

        Features and Advantages:
        * Xenicane diterpenes from Cnidaria
        * Exhibit strong antileishmanial activity against Leishmania Amazonensis (IC50 = 38 ng/mL)
        * Low cytotoxicity (IC50 on HeLa cells = 2000 ng/mL, IC50 on P388 cells = 890 ng/mL)
        * Also exhibit effect against Trypanosoma Congolense (sleeping sickness) and Plasmodium Falciparum (malaria)
        * US provisional patent application filed

        Possible Applications:
        Lead compounds for antiprotozoal drugs

        Full details Contact close
      • Therapeutic Peptide for Allergic DiseasesTherapeutic Peptide for Allergic Diseases
          Preview
          Description

          The inventor has newly developed an inhibitory peptide of human mast cell activation for the treatment of allergic diseases. There are increasing evidences that mast cells from different species are functionally heterogeneous so that the known anti-allergic agents such as SCG and NS have much less effect on human mast cells compared to murine mast cells. Therefore, the proposed peptide which targets human IgE receptor (FceRIbeta) expressed on human mast cells can be a promising drug for the treatment of allergic diseases. Furthermore, the FceRIbeta is expressed exclusively on the surface of mast cells and basophils, suggesting the peptide has no potential side effect. Also, the cost is much lower than anti-IgE recombinant humanized monoclonal antibody, which is only drug that inhibits human mast cell activation but pretty expensive.

          Features and Advantages
          * 25-amino acid peptides (can be shortened to 17 amino acids)
          * Recombinant cell-penetrating form of phosphorylated FcERI beta ITAM
          * Inhibits IgE-dependent human mast cell activation by disturbing the interaction between a Src kinase Lyn and phosphorylated endogenous FceR1 beta ITAM
          * Significantly inhibited IgE-dependent human mast cell activation in vitro
          * Effectively inhibited hypersensitivity reactions in murine models in vivo
          * PCT application filed

          Possible Applications
          * Human allergic diseases
          - Allergic brochial asthma, atopic dermatitis, acute and chronic urticeria
          - Food allergy, anaphylaxis, allergic rhinitis, vernal keratoconjunctivitis


          The pdf file with more detailed information is available at
          http://www.japantechnologygroup.com/seeds/JTGseeds_Therapeutic_Peptide.pdf

          Full details Contact close
        • Peptide Tag for Stabilizing Protein in the CellPeptide Tag for Stabilizing Protein in the Cell
            Preview
            Description

            The proposed technology is a protein motif that enables the stabilization of proteins in the cell. The motif is composed of 16 amino acids mainly consisting of acidic amino acids. This motif provides proteolysis resistance to the fused protein, so that the expression level is highly improved by approximately 2-20 times. By employing this motif as a tag of the expression plasmid, it is possible to provide an expression system that can raises the expression of proteins which are normally expressed at a low level. Furthermore, as the other application, applying this motif to cell-permeable proteins used for protein therapies would result in the improvement of the effectiveness of the therapies, since the protein therapies generally face the problems of the protein degradation.

            Features and Advantages
            * Motif derived from transcription factor DP-1, and named as DP-1 Stabilon
            - Provides proteolysis resistance by inhibiting proteasome and serine protease
            - Composed of 16 amino acids mainly consisting of acidic ones (EDDEEDDDFNENDEDD)
            - Can be shortened to 5 acidic amino acids (EDDEE)
            - Has effect in both positions of N-terminus and C-terminus to be selected
            * The expression of many proteins increased (approx. 2-20 times)
            - eg. Sox2, PARalpha, Foxp3, Oct4, Klf4, Glis1, NFYC, HSPA14 and RhoA
            * PCT application filed

            Possible Applications
            * Tag for plasmid systems to improve protein expression
            * Stabilization of therapeutic proteins, therapeutic antibodies

            Full details Contact close
          • Novel Mouse Model for Rheumatoid ArthritisNovel Mouse Model for Rheumatoid Arthritis
              Preview
              Description

              Provided is a new animal model for human rheumatoid arthritis (RA), which is produced by inoculating Epstein-Barr virus (EBV). A number of observations have suggested the involvement of EBV in the pathogenesis of RA. However, there have been no appropriate animal models for EBV infection to examine a causal relationship between EBV and RA, because EBV can infect only limited primate species and does not infect normal mice. By employing the NOD/Shi-scid/IL-2Rynull (NOG) mouse strain, the inventor has successfully developed humanized mouse model of EBV infection. This newly developed animal model shows erosive arthritis with many features resembling those of RA so that be useful for pathological elucidation and drug evaluation of RA. Furthermore, this animal model has advantages over conventional RA animal models in that it can be produced easily with low cost and suitable for examining development and progress of inflammation.

              Features and Advantages
              * Human immune system components are reconstituted in NOG mice
              - CD34+ hematopoietic stem cells isolated from cord blood is transplanted in NOG mice
              * Erosive arthritis is accompanied by many features resembling RA
              - Pannus formation, synovial membrane proliferation,
              - Inflammatory cell infiltration to the synovium, and bone marrow edema
              * Slow development and progression of inflammation like those of human RA
              - Suitable for pathological elucidation and drug evaluation
              * Simple and low-cost production method
              * PCT application filed

              Possible Applications
              * Animal experiment for drug development and pathological elucidation of RA

              Full details Contact close
            • Bone marrow-directing drug delivery materialsBone marrow-directing drug delivery materials
                Preview
                Description

                The bone marrow play an important role as a hematopoietic organ, and bone diseases such as osteomyelitis and myeloma cause severe morbidity. Since the bone marrow is not an organ to which surgical therapy is an option, the bone marrow diseases are mainly subject to medical treatment, such as by chemotherapy. There is a great need for drug delivery systems that have the ability to effectively deliver therapeutic agents to the bones or bone marrows. The inventors have identified novel drug delivery materials that have the ability to target therapeutic agents to the bones with high specificity. These agents also have the ability to result in accumulation of therapeutic agents in bones or bone marrow. This is based on the fact that the vesicles were intravenously administered to a living body and the distribution of the vesicles in the organs in the body was quantitatively analyzed. The experiments have been conducted using rabbit and monkeys.

                Features and Advantages:
                * Nano-sized lipid vesicles (liposome technology)
                * Surface modification of the vesicles with carboxylic acids (SA) and polyethylene glycol (PEG) chains
                * Bone marrow-directing drug delivery material (Intravenous infusion)
                * Site-specific drug delivery system targeting bone marrow for various drugs
                * High blood compatibility and biodegradability

                Possible Applications:
                Drug delivery material which may be used in various applications such as diagnosis, treatment of prevention of diseases of bone, bone marrow, cartilage, and joint

                Full details Contact close
              • Apoptosis-Inducing Peptide for Cancer Gene TherapyApoptosis-Inducing Peptide for Cancer Gene Therapy
                  Preview
                  Description

                  Provided is a multifunctional peptide which can induce apoptosis, increase of transfection efficiency with non-viral vectors, and increase of deposition of other proteins in extracellular matrix and therefore resulting in high local concentration of target proteins. The combination of these functions is ideal for improvement of apoptosis-based therapies for cancers. Currently, the inventor has been developing the combinational use of the proposed peptide and Fas-ligand (FasL) for gene therapy of oral and neck tumors. In vivo study using model mice with explanted tumors has shown that this peptide fragment can substantially improve the efficiency of cancer gene therapy using FasL. In fact, some tumors treated by the fused protein of FasL and this peptide completely disappeared.

                  Features and Advantages
                  * E3 and C1 domains of Del1, extracellular matrix (ECM) protein
                  - Proteins fused to the E3 and C1 domains are deposited in the ECM
                  - E3 also increases the endocytosis of transfected genes
                  - E3 induces apoptosis at high concentration
                  * Fusion protein of FasL and E3C1 can be used for improved cancer gene therapy
                  - Local injection of the fusion protein using non-viral vectors
                  - Injected protein is locally concentrated and retained due to its deposition activity
                  - Safer and more economical than therapy by viral vector

                  Possible Applications
                  * Cancer gene therapy

                  Full details Contact close
                • Single-stranded DNA Catenation EnzymeSingle-stranded DNA Catenation Enzyme
                    Preview
                    Description

                    Provided is a novel method for single-stranded DNA (ssDNA) catenation, comprising ssDNA cutting and binding reactions. There is an increasing interest in methods for manipulating ssDNA, with the advance of genetic engineering techniques. However, only a limited number of techniques have been reported for manipulating ssDNA, especially for binding. It can be anticipated that this novel method will contribute to the elucidation of the generation of genetic disorder and new drug discovery.

                    Features and Advantages
                    EVL (human Ena/Vasp-like protein): ssDNA catenation enzyme
                    * Stability of EVL: Storable at -80 degrees C
                      -Stable for 1-2 years at deepfreeze (30% glycerol stock); capable of refreezing and rethawing
                    * Preparation of EVL: Mass expression and recombinant purification using E.coli
                      -Purifiable as His-Tag fusion protein (4-step purification)
                    * Quality control of EVL: Electrophoresis
                    * Activity confirmation of catenation: Electrophoresis and electronmicroscopy
                    * Regulation of the efficiency of catenation
                      -Efficiency is increased with addition of TopoI (10%->50%)
                      -Efficiency is controllable with Mg2+ concentration

                    Possible Applications:
                    * Reagent for genetic engineering: ssDNA catenation reagent, molecular size marker
                    * Screening tool: screening for the treatment of genetic disorder
                    * DNA therapy: treatment using ssDNA

                    Full details Contact close